News | May 13, 2021
COVAXIN phase II/III clinical trial approved for 2-18 years
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
BBIL had proposed to carry out Phase II/III clinical trial of Covaxin in the age group of 2 to 18 years
Baricitinib is an oral medication that was earlier registered in India for the treatment of moderate to severe active rheumatoid arthritis in adult patients.
This oxygen is being provided free-of-cost to several state governments across the country to bring immediate relief to over 1 lakh patients on a daily basis
The U.S. Development Finance Corporation is funding a substantial expansion of manufacturing capability for BioE, the vaccine manufacturer in India
_256_384.jpeg)
Against the present demand from 20 states of 6,785 MT/day of Liquid Medical Oxygen, the Government of India has from 21st April allocated 6,822 MT/day to these states
The company also plans to register the similar range of products in the neighbouring countries.
Lonza's Ibex Design end-to-end offering will cover the development stages of IMT-009 from development candidates through early clinical studies
Both the vaccines have been extensively tested by IVRI for safety and potency and have been found to provide 100% protection
Bharat Biotech expects to share further details of the trial results as additional data become available.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
Subscribe To Our Newsletter & Stay Updated
